Holen Sie sich die Stockscreener-App
149.34
3.98%
5.72
Handel nachbörslich:
149.34
Schlusskurs vom Vortag:
$143.62
Offen:
$145
24-Stunden-Volumen:
352.82K
Relative Volume:
0.93
Marktkapitalisierung:
$4.32B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
49.95
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
+9.81%
1M Leistung:
+0.79%
6M Leistung:
-4.12%
1J Leistung:
-20.34%
1-Tages-Spanne:
$145.00
$151.61
1-Wochen-Bereich:
$132.31
$151.61
52-Wochen-Spanne:
$122.80
$207.84
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Vergleichen Sie KRYS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
149.34 | 3.98B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Evercore Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $200 - 富途牛牛
Astrana Health And 2 Insider Favorites For High Growth - simplywall.st
Krystal Biotech’s Earnings Call: Strong Growth Amid Challenges - MSN
Krystal Biotech, Inc. (NASDAQ:KRYS) Q2 2025 Earnings Call Transcript - MSN
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Krystal Biotech sees global VYJUVEK expansion and expects Q3 revenue dip before renewed growth - MSN
Palmoplantar Keratoderma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc. - Barchart.com
Local biotech co-founder named to Forbes 50 Over 50 - MSN
Krystal Biotech Analyst Ratings: Bullish Sentiment with 6 Buy Ratings - AInvest
Krystal Biotech Q2 Earnings Call: Strong Growth Amid Challenges - AInvest
Krystal Biotech Shares Rise After Q2 Earnings, Revenue Beat Expectations - MSN
Krystal Biotech: Citigroup maintains Neutral, PT down to $166 from $176. - AInvest
Reassessing Krystal Biotech: Navigating Short-Term Volatility to Unlock Long-Term Value - AInvest
Krystal Biotech price target lowered to $182 from $192 at BofA - Yahoo Finance
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $166 to $240 - 富途牛牛
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook - Yahoo Finance
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
Krystal Biotech Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Krystal Biotech Reports Strong Q2 2025 Results - TipRanks
Krystal Biotech price target lowered to $166 from $176 at Citi - TipRanks
Krystal Biotech stock price target lowered to $182 at BofA on growth concerns - Investing.com Nigeria
Krystal Biotech Plummets 14.04% on Record $290M Trading Volume Ranks 382nd Amid Surging Revenue and Regulatory Momentum - AInvest
Krystal Biotech Exceeds Q2 2025 Earnings Estimates with $96 Million Revenue, $1.33 EPS - AInvest
Krystal Biotech sees revenue growth but anticipates dip due to summer vacations - The Business Journals
Contradictions Unveiled: Krystal Biotech's Q2 2025 Earnings Call Reveals Conflicting Insights on VYJUVEK Sales and Market Strategy - AInvest
Krystal Biotech, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech: Strong Financial Performance and Strategic Global Expansion Justify Buy Rating - TipRanks
Krystal Biotech shares fall 12.71% intraday after missing Q2 earnings estimates. - AInvest
Krystal Biotech Q2 2025 slides: VYJUVEK drives growth amid global expansion - Investing.com Canada
Earnings call transcript: Krystal Biotech Q2 2025 beats forecasts, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Krystal Biotech Q2 2025 beats forecasts, stock dips - Investing.com Canada
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates - sharewise.com
Transcript : Krystal Biotech, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
Krystal Biotech shares jump as Q2 results exceed expectations By Investing.com - Investing.com India
Krystal Biotech shares jump as Q2 results exceed expectations - Investing.com
Krystal Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Krystal Biotech Grows Revenue On VYJUVEK’s Expanding Global Reach - Finimize
Krystal Biotech Q2 Earnings, Revenue Rise - MarketScreener
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q2 Revenue $96.0M, vs. FactSet Est of $92.0M - MarketScreener
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results - TradingView
Krystal Biotech earnings beat by $0.07, revenue topped estimates - Investing.com Canada
Krystal Biotech, Inc. SEC 10-Q Report - TradingView
Krystal Biotech's Q2 revenue rises 37% to $96 mln - MarketScreener
Krystal Biotech, Inc. Q2 Profit Advances, But Misses Estimates - Nasdaq
Press Release: Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results - 富途牛牛
What drives Krystal Biotech Inc. stock priceGrow your portfolio with growth-oriented stocks - Jammu Links News
Is Krystal Biotech Inc. a good long term investmentUnlock real-time stock alerts for quick profits - Jammu Links News
How volatile is Krystal Biotech Inc. stock compared to the marketTrack emerging stocks with high growth potential - Jammu Links News
What are analysts’ price targets for Krystal Biotech Inc. in the next 12 monthsInvest smarter with expert stock recommendations - Jammu Links News
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):